fertility

INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

Stock Price Surge and Aftermath INVO Fertility’s stock took Wall Street by surprise this week with a massive one-day surge. On October 16, shares of the micro-cap fertility clinic operator opened around $0.75 and skyrocketed nearly 90% by day’s end, closing at approximately $1.43 ts2.tech. Intra-day, the price briefly hit $2+ per share, a huge jump from the prior day’s close under $0.80 ts2.tech. To put this in perspective, such a single-day leap is virtually unheard of for most stocks – even in the volatile biotech space – and far outpaced broader market moves. Trading volume spiked astronomically during the

17 October 2025

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

FEMY Stock Soars on Fertility Buzz Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior, and well off its 52-week low near $0.31 ts2.tech. On October 16, the stock spiked dramatically: opening near $0.55, it rallied to an intraday high of $0.84 (+52%) before settling at $0.745 (+35%) by the close finance.yahoo.com. This explosive move came amid unusually heavy volume (tens of millions of shares traded, versus ~7 million on a typical day) stockinvest.us, indicating

17 October 2025

Biotechnology · FDA Updates · Fertility · Medical Innovations · NASDAQ:FEMY · Stock Market

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination globenewswire.com stocktitan.net. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery ir.femasys.com ir.femasys.com. This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected

16 October 2025

FDA Approvals · Fertility Technology · Healthcare Innovation · Investment News · NASDAQ:FEMY · Stock Market

INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

Stock Price Soars Nearly 90% in One Day INVO Fertility’s stock took investors on a wild ride on Oct. 16, skyrocketing almost 90% by the closing bell reuters.com. Shares opened at just $0.75 and, in an astonishing surge, hit $1.43 by day’s end (after touching $2+ at the peak) reuters.com. To put the move in perspective, INVO’s daily gain far outpaced the broader market, and such a jump is highly unusual – even in the volatile biotech sector. Trading volume exploded to over 108 million shares reuters.com, dwarfing the typical daily volume (around ~33,000 shares) and exceeding the company’s entire

16 October 2025

Business Trends · Fertility Industry · Health News · Investing · NASDAQ:IVF · Stock Market